XILIO THERAPEUTICS INC. - COMMON STOCK

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

20 янв 2022 07:30:00 Источник Nasdaq GlobeNewswire

Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors

06 янв 2022 07:30:00 Источник Nasdaq GlobeNewswire

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

02 дек 2021 07:30:00 Источник Nasdaq GlobeNewswire

Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

12 ноя 2021 07:00:03 Источник Nasdaq GlobeNewswire

Xilio Therapeutics Announces Closing of Initial Public Offering

26 окт 2021 16:05:00 Источник Nasdaq GlobeNewswire